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Author’s response
In response to the letter of Aydogan et al. [1] 
concerning our study entitled “The infl uence of 
acute pulmonary embolism on early and delayed 
prognosis for patients with chronic heart failure” 
published in Cardiology Journal [2] we agree that 
in order to assess major risk factors for mortality 
in patients with chronic heart failure (CHF) large-
-scale prospective randomized studies in this group 
of patients would be of value. It is clear that not only 
co-morbidities in CHF but also medication used 
for treatment of co-morbidities and the patients’ 
lifestyles affect complications and the prognosis 
in this group of patients [3]. Aydogan et al. [1] 
suggested that the treatment of acute pulmonary 
embolism (APE) in CHF patients should be longer 
than the standard 3-month treatment. Authors also 
stated that CHF is an irreversible and persistent, 
chronic risk factor for APE and therefore anticoa-
gulants should be prescribed for life long therapy. 
However, according to the current quidelines, 
CHF is only a moderate risk factor for APE, and in 
patients with the fi rst episode of APE it does not 
imply a treatment longer than 3 months, unlike 
in the case of neoplasm or some severe throm-
bophilias when long-term anticoagulant therapy 
is justifi ed [4]. We fully agree that CHF patients 
are at a greater risk of thromboembolic complica-
tions. In our study we have also proven that APE 
is an independent risk factor for an early death 
in CHF patients; we have additionally suggested 
that standard secondary prophylaxis following an 
acute episode of pulmonary embolism maybe in-
suffi cient for this group of patients. We think that 
CHF patients with the fi rst APE episode is not 
a homogenous group. Most probably it includes 
high and low risk patients of APE recurrence. 
Therefore it seems justifi ed to create and defi ne 
a scale which will be helpful for the assessment of 
APE recurrence. Such scale could follow the idea 
of CHADS2-VASC score currently used for risk 
stratification of thromboembolic complications 
in patients with atrial fi brillation [5]. We are sure 
that despite similar degree of left ventricular dys-
function elderly patients in NYHA functional class 
III with limited mobility are at higher risk of APE 
recurrence than younger ones with successful CHF 
therapy and no activity limitations. Perhaps CHF 
patients with high risk of APE recurrence should 
be treated with anticoagulant therapy much longer 
and even more intensely during the fi rst months. 
Similarly to Aydogan et al. [1], we also have many 
questions and doubts concerning the treatment 
of patients with CHF and APE, and that is why 
we once again stress that large-scale randomized 
studies assessing these patients are vital. 
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